![]() Risedronic acid structure
|
Common Name | Risedronic acid | ||
---|---|---|---|---|
CAS Number | 105462-24-6 | Molecular Weight | 283.112 | |
Density | 1.9±0.1 g/cm3 | Boiling Point | 692.3±65.0 °C at 760 mmHg | |
Molecular Formula | C7H11NO7P2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 372.5±34.3 °C |
Use of Risedronic acidRisedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: OthersRisedronate, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy .The administration of 20 and 25 mg/kg risedronate for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls . |
Name | Risedronic Acid |
---|---|
Synonym | More Synonyms |
Description | Risedronic acid (Risedronate ) is a pyridinyl biphosphonate which inhibits osteoclast-mediated bone resorption.Target: OthersRisedronate, which was promoted in Croatia a few months ago, is the latest (III) generation of bisphosphonates, the most efficient anti-resorption drugs that inhibit osteoclast-mediated bone resorption and change the bone metabolism. Risedronate is hence the first line of bisphosphonates for the reduction of vertebral and non-vertebral fracture risks in postmenopausal women with osteoporosis or those with a high risk of osteoporosis. It also efficiently prevents bone loss or improves bone density in men and women on a long-term corticosteroid therapy .The administration of 20 and 25 mg/kg risedronate for 4 days led to decreases of parasitemia of 68.9% and 83.6%, respectively. On the seventh day of treatment the inhibitions were 63% and 88.9% with 20 and 25 mg/kg, respectively. After recovering the parasitemia, a dose-response curve was obtained for estimating the ID50 (dose causing 50% inhibition), equivalent to 17 ± 1.8 mg/kg after 7 days of treatment. Four days after the interruption of treatment (11 days postinfection), the parasitemias of the groups treated with 10, 15, 20, and 25 mg/kg/day were 15.3%, 15.9%, 15.2%, and 5.7%, respectively. Conversely, the group that received PBS presented parasitemia of 25.6%. Among the groups treated with risedronate, only the animals that received 25 mg/kg had a significant inhibition of 77.8% (see Table S1 in the supplemental material), demonstrating that even after treatment discontinuation, the parasitemia of the animals remained low in relation to that of the controls . |
---|---|
Related Catalog | |
References |
Density | 1.9±0.1 g/cm3 |
---|---|
Boiling Point | 692.3±65.0 °C at 760 mmHg |
Molecular Formula | C7H11NO7P2 |
Molecular Weight | 283.112 |
Flash Point | 372.5±34.3 °C |
Exact Mass | 283.001068 |
PSA | 167.80000 |
LogP | -2.94 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.651 |
Storage condition | 2~8°C |
Hazard Codes | Xi |
---|---|
WGK Germany | 3.0 |
HS Code | 2933399090 |
~98% Risedronic acid CAS#:105462-24-6 |
Literature: JUBILANT ORGANOSYS LIMITED Patent: WO2006/51553 A1, 2006 ; Location in patent: Page/Page column 8 ; |
~81% Risedronic acid CAS#:105462-24-6 |
Literature: FLEMING LABORATORIES LIMITED Patent: WO2009/34580 A1, 2009 ; Location in patent: Page/Page column 7 ; |
~82% Risedronic acid CAS#:105462-24-6 |
Literature: ZAKLADY FARMACEUTYCZNE S.A.; POLITECHNIKA GDANSKA Patent: WO2006/71128 A1, 2006 ; Location in patent: Page/Page column 4; 5 ; |
~% Risedronic acid CAS#:105462-24-6 |
Literature: WO2008/58722 A1, ; Page/Page column 11-12 ; |
~% Risedronic acid CAS#:105462-24-6 |
Literature: WO2008/44245 A2, ; Page/Page column 5 ; |
~% Risedronic acid CAS#:105462-24-6 |
Literature: US5391743 A1, ; |
~% Risedronic acid CAS#:105462-24-6 |
Literature: Phosphorus, Sulfur and Silicon and the Related Elements, , vol. 188, # 1-3 p. 39 - 41 |
HS Code | 2933399090 |
---|---|
Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Actonel |
Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis- |
[1-Hydroxy-2-(3-pyridinyl)-1,1-ethanediyl]bis(phosphonic acid) |
(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid |
(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid) |
MFCD00867080 |
T6NJ C1XQPQQO&PQQO |
[1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid |
2-(3-Pyridinyl)-1-hydroxyethanediphosphonic acid |
[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis(phosphonic acid) |
Risedronic acid |
[1-Hydroxy-2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid) |
Atelvia |